New research suggests that there may be limits to how many tricks the coronavirus has up its sleeve.
Faye Flam, Tribune News Service
It’s been about a year since the early coronavirus alarms were raised, and despite a decline in infections, new fears are rising up. New COVID-19 variants are making pessimists worry that an even bigger next wave may be coming.
It’s true that the virus is mutating in ways more profound than biologists anticipated last summer. But new research also suggests that there may be limits to how many tricks the coronavirus has up its sleeve — and that may make it easier for vaccines to keep up.
If scientists have been somewhat blindsided by the variants, it’s because they hadn’t fully realized the way the coronavirus tends to mutate — in a way that’s distinct from influenza or HIV. This virus has a talent for shape-shifting by dropping pieces of its genetic code.
Early on, a few scientists observed these so-called deletion mutations by studying virus samples from patients with compromised immune systems. Such patients can be crucibles for viral evolution, because the virus survives in their cells for months, making copies of itself all the while.
The mutations that scientists were observing in individual patients were essentially the same as those now seen in the new variants. Molecular biologist Kevin McCarthy of the University of Pittsburgh, who analysed mutations in immune-compromised patients, found this eye-opening. “Evolution in that patient, in some ways, foreshadowed what the virus was going to do all over the world,” he said.
McCarthy’s group published its findings earlier this month in Science. Another group of researchers published a similar comparison in December in the New England Journal of Medicine.
Last spring and summer, scientists had considered SARS-CoV-2 to be somewhat mutation-averse, because it contains a molecular proofreading mechanism. When a mutated virus replicates, this mechanism corrects it. Human cells and those of other animals have various such proofreading systems to allow them to replicate without too many errors. Influenza viruses and HIV do not — which is one reason those viruses continue to evolve too fast for a single vaccine.
However, it turns out that the coronavirus’s proofreader lets one type of mutation through: a section of missing genetic code. So the virus is able to eject sections of code and still replicate — and still get transmitted to other people.
If the coronavirus develops an anti-vaccine strategy, we will need a counter strategy.
That could mean upgrading the existing vaccines so that they induce a broader range of antibodies. It also might help to give people different vaccines for their first and second doses — an approach that needs to be tested in clinical trials.
McCarthy would like to see more data on the patients who have gotten COVID-19 despite being vaccinated. When were they exposed, and did they have high or low levels of the virus in their bodies? This fight requires that all scientists working to understand the virus have all the data they need.
But from what they’ve learned so far, it doesn’t appear that the new variants mean the pandemic will never end. McCarthy thinks SARS-CoV-2 may not be able to mutate itself in infinite ways that make it better at infecting people and evading antibodies. So far, scientists have been seeing the same deletions cropping up again and again. “The virus was telling us that it was evolving in a certain way for a certain reason,” he said.
At this point, new changes are appearing independently in different places — so-called convergent evolution — and it could be that the number of possible changes is limited.
A year ago, some people thought the course of the pandemic could be foretold according to simple formulas. As the complexities of the coronavirus have become apparent, scientists have grown less confident in their predictions. But that also means there’s no reason to assume the pandemic will never go away.
This has reference to your report, “Italian researchers claim world’s first coronavirus vaccine” (May 6). Billions of citizens across the world, irrespective of religion, ideology, caste and creed, wait with bated breath, for scientists to discover a vaccine to fight coronavirus. Never before, has the discovery of a new product, been so critical. Over a hundred research institutions are burning the midnight oil to find a vaccine including the Oxford University, Massachusetts-based Moderna, Beijing-based Sinovac, Biotech Pfizer and BioNtech, Inovio Pharmaceuticals and the Bacillus Calmette-Guerin (BCG).
Recent news from researchers at Oxford University gives some hope that a vaccine for COVID-19 could be ready as early as this fall. But as with test kits, N95 masks and ventilators, the demand will far exceed the supply — at least initially. So, who should be first in line for a vaccination once it is available?
A World Health Organisation (WHO) top-level official has estimated that the vaccine against the SARS-CoV2-causing Novel Coronavirus (COVID19) would only be available in two-and-a half years time.
When pharmaceutical company Moderna issued a press release about the promising results of its Phase I clinical trial for a coronavirus vaccine, the media and the markets went wild. The New York Times ran a story that went viral on Twitter, racking up millions of views as social media influencers and doctors alike shared it far and wide. Moderna’s stock price shot up 20 per cent and several peer companies like Novavax rallied even higher at more than 30 per cent.
Dating during the pandemic is becoming less complicated and risky for attorney Shelley O’Connor. Luis Parocua Jr. is no longer awakened by COVID-19 nightmares, triggered by the devastation he saw at his former hospital job.
After a new leadership team took over the government in the tiny western Balkan nation of Montenegro for the first time in decades and began looking through the books, they found what they described as shocking levels of corruption under the
Exactly a year after New Zealand recorded its first coronavirus case, the biggest city of Auckland woke up on Sunday to a second lockdown this month, as authorities try to keep a cluster of the more contagious UK variant in check.
Apricity. If you live in or near Chicago — or any place where the grey skies have brightened lately and you no longer feel as cold as death — this is the word you’ve been looking for. Even if you didn’t know you were looking for it, it’s the word you’ve